Top

Knee Surgery, Sports Traumatology, Arthroscopy

Published in:

01-05-2009 | Sports Medicine

Use of bisphosphonates for the treatment of stress fractures in athletes

Authors: Yosuke Shima, Lars Engebretsen, Junji Iwasa, Katsuhiko Kitaoka, Katsuro Tomita

Published in: Knee Surgery, Sports Traumatology, Arthroscopy | Issue 5/2009

Abstract

A literature review was performed to investigate the potential role of bisphosphonates for the treatment of stress fractures in athletes. Given the inhibitory action on osteoclast-mediated bone resorption, short-term suppression of bone remodeling using bisphosphonates could potentially treat stress fractures and prevent stress fractures from becoming regular fractures. To date, while there are some animal studies showing the scientific basis of bisphosphonates on stress fractures, there is still no conclusive evidence to prove any effect of bisphosphonates on stress fracture healing in humans. Further well-designed clinical trials should be carried out to establish their usefulness and safety. Until the results are available, it is prudent to limit the use of bisphosphonates for the treatment of stress fractures.

Adami S, Bhalla AK, Dorizzi R, Montesanti F, Rosini S, Salvagno G, Lo Cascio V (1987) The acute-phase response after bisphosphonate administration. Calcif Tissue Int 41:326–331PubMedCrossRef

Ali SM, Esteva FJ, Hortobagyi G, Harvey H, Seaman J, Knight R, Costa L, Lipton A (2001) Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol 19:3434–3437PubMed

Allen MR, Iwata K, Phipps R, Burr DB (2006) Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone 39:872–879PubMedCrossRef

Amanat N, Brown R, Bilston LE, Little DG (2005) A single systemic dose of pamidronate improves bone mineral content and accelerates restoration of strength in a rat model of fracture repair. J Orthop Res 23:1029–1034PubMedCrossRef

Amanat N, McDonald M, Godfrey C, Bilston L, Little D (2007) Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair. J Bone Miner Res 22:867–876PubMedCrossRef

Barrett JG, Sample SJ, McCarthy J, Kalscheur VL, Muir P, Prokuski L (2007) Effect of short-term treatment with alendronate on ulnar bone adaptation to cyclic fatigue loading in rats. J Orthop Res 25:1070–1077PubMedCrossRef

Bauss F, Schenk RK, Hört S, Müller-Beckmann B, Sponer G (2004) New model for simulation of fracture repair in full-grown beagle dogs: model characterization and results from a long-term study with ibandronate. J Pharmacol Toxicol Methods 50:25–34PubMedCrossRef

Bennell KL, Malcolm SA, Brukner PD, Green RM, Hopper JL, Wark JD, Ebeling PR (1998) A 12-month prospective study of the relationship between stress fractures and bone turnover in athletes. Calcif Tissue Int 63:80–85PubMedCrossRef

Berenson JR, Rosen L, Vescio R, Lau HS, Woo M, Sioufi A, Kowalski MO, Knight RD, Seaman JJ (1997) Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function. J Clin Pharmacol 37:285–290PubMed

10.

Bilezikian JP (2006) Osteonecrosis of the jaw—do bisphosphonates pose a risk? N Engl J Med 355:2278–2281PubMedCrossRef

11.

Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR, FLEX Research Group (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the fracture intervention trial long-term extension (FLEX): a randomized trial. JAMA 296:2927–2938PubMedCrossRef

12.

Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR, HORIZON Pivotal Fracture Trial (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822PubMedCrossRef

13.

Body JJ, Mancini I (2002) Bisphosphonates for cancer patients: why, how, and when? Support Care Cancer 10:399–407PubMedCrossRef

14.

Body JJ (2005) Bisphosphonates in metastatic bone disease: renal safety matters. Oncologist 10:1–2PubMedCrossRef

15.

Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA, Alendronate Phase III Osteoporosis Treatment Study Group (2004) Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189–1199PubMedCrossRef

16.

Bransford R, Goergens E, Briody J, Amanat N, Cree A, Little D (2007) Effect of zoledronic acid in an L6–L7 rabbit spine fusion model. Eur Spine J 16:557–562PubMedCrossRef

17.

Burr DB, Milgrom C, Boyd RD, Higgins WL, Robin G, Radin EL (1990) Experimental stress fractures of the tibia. Biological and mechanical aetiology in rabbits. J Bone Joint Surg Br 72:370–375PubMed

18.

Burr DB, Forwood MR, Fyhrie DP, Martin RB, Schaffler MB, Turner CH (1997) Bone microdamage and skeletal fragility in osteoporotic and stress fractures. J Bone Miner Res 12:6–15PubMedCrossRef

19.

Burr DB (2001) Pharmaceutical treatments that may prevent or delay the onset of stress fractures. In: Burr DB, Milgrom C (eds) Muscloskeletal fatigue and stress fractures. CRC Press, Boca Raton, pp 259–270

20.

Cao Y, Mori S, Mashiba T, Westmore MS, Ma L, Sato M, Akiyama T, Shi L, Komatsubara S, Miyamoto K, Norimatsu H (2002) Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res 17:2237–2246PubMedCrossRef

21.

Eisman JA, Civitelli R, Adami S, Czerwinski E, Recknor C, Prince R, Reginster JY, Zaidi M, Felsenberg D, Hughes C, Mairon N, Masanauskaite D, Reid DM, Delmas PD, Recker RR (2008) Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA Study. J Rheumatol 35:488–497PubMed

22.

Ezra A, Golomb G (2000) Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv Drug Deliv Rev 42:175–195PubMedCrossRef

23.

Felix R, Bettex JD, Fleisch H (1981) Effect of diphosphonates on the synthesis of prostaglandins in cultured calvaria cells. Calcif Tissue Int 33:549–552PubMedCrossRef

24.

Flinn SD (2002) Changes in stress fracture distribution and current treatment. Curr Sports Med Rep 1:272–277PubMed

25.

Flora L, Hassing GS, Cloyd GG, Bevan JA, Parfitt AM, Villanueva AR (1981) The long-term skeletal effects of EHDP in dogs. Metab Bone Dis Relat Res 3:289–300PubMedCrossRef

26.

Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, Clézardin P (2002) Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62:6538–6544PubMed

27.

Gehrmann RM, Renard RL (2006) Current concepts review: Stress fractures of the foot. Foot Ankle Int 27:750–757PubMed

28.

Hame SL, LaFemina JM, McAllister DR, Schaadt GW, Dorey FJ (2004) Fractures in the collegiate athlete. Am J Sports Med 32:446–451PubMedCrossRef

29.

Hausman MR, Schaffler MB, Majeska RJ (2001) Prevention of fracture healing in rats by an inhibitor of angiogenesis. Bone 29:560–564PubMedCrossRef

30.

Jackson G (2005) Safety and compliance of intravenous and oral dosing regimens. Oncologist 10:313–314PubMedCrossRef

31.

Kaeding CC (2006) Stress fractures. Clin Sports Med 25:15–16CrossRef

32.

Koester MC, Spindler KP (2006) Pharmacologic agents in fracture healing. Clin Sports Med 25:63–73PubMedCrossRef

33.

Korpelainen R, Orava S, Karpakka J, Siira P, Hulkko A (2001) Risk factors for recurrent stress fractures in athletes. Am J Sports Med 29:304–310PubMed

34.

Kurth AH, Eberhardt C, Müller S, Steinacker M, Schwarz M, Bauss F (2005) The bisphosphonate ibandronate improves implant integration in osteopenic ovariectomized rats. Bone 37:204–210PubMedCrossRef

35.

Lai KA, Shen WJ, Yang CY, Shao CJ, Hsu JT, Lin RM (2005) The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study. J Bone Joint Surg Am 87:2155–2159PubMedCrossRef

36.

Lenart BA, Lorich DG, Lane JM (2008) Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 358:1304–1306PubMedCrossRef

37.

Li C, Mori S, Li J, Kaji Y, Akiyama T, Kawanishi J, Norimatsu H (2001) Long-term effect of incadronate disodium (YM–175) on fracture healing of femoral shaft in growing rats. J Bone Miner Res 16:429–436PubMedCrossRef

38.

Lin JH (1996) Bisphosphonates: a review of their pharmacokinetic properties. Bone 18:75–85PubMedCrossRef

39.

Little DG, Cornell MS, Hile MS, Briody J, Cowell CT, Bilston L (2001) Effect of pamidronate on distraction osteogenesis and fixator-related osteoporosis. Injury 32:SD14–SD20PubMedCrossRef

40.

Little DG, Smith NC, Williams PR, Briody JN, Bilston LE, Smith EJ, Gardiner EM, Cowell CT (2003) Zoledronic acid prevents osteopenia and increases bone strength in a rabbit model of distraction osteogenesis. J Bone Miner Res 18:1300–1307PubMedCrossRef

41.

Little DG, Peat RA, Mcevoy A, Williams PR, Smith EJ, Baldock PA (2003) Zoledronic acid treatment results in retention of femoral head structure after traumatic osteonecrosis in young Wistar rats. J Bone Miner Res 18:2016–2022PubMedCrossRef

42.

Little DG, McDonald M, Bransford R, Godfrey CB, Amanat N (2005) Manipulation of the anabolic and catabolic responses with OP-1 and zoledronic acid in a rat critical defect model. J Bone Miner Res 20:2044–2052PubMedCrossRef

43.

Macarol V, Fraunfelder FT (1994) Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthalmol 118:220–224PubMed

44.

Martin B (1995) Mathematical model for repair of fatigue damage and stress fracture in osteonal bone. J Orthop Res 13:309–316PubMedCrossRef

45.

Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115–1117PubMedCrossRef

46.

Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB (2000) Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15:613–620PubMedCrossRef

47.

Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB (2001) Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28:524–531PubMedCrossRef

48.

Milgrom C, Simkin A, Eldad A, Nyska M, Finestone A (2000) Using bone’s adaptation ability to lower the incidence of stress fractures. Am J Sports Med 28:245–251PubMed

49.

Milgrom C, Finestone A, Sharkey N, Hamel A, Mandes V, Burr D, Arndt A, Ekenman I (2002) Metatarsal strains are sufficient to cause fatigue fracture during cyclic overloading. Foot Ankle Int 23:230–235PubMed

50.

Milgrom C, Finestone A, Novack V, Pereg D, Goldich Y, Kreiss Y, Zimlichman E, Kaufman S, Liebergall M, Burr D et al (2004) The effect of prophylactic treatment with risedronate on stress fracture incidence among infantry recruits. Bone 35:418–424PubMedCrossRef

51.

Miltner O, Niedhart C, Piroth W, Weber M, Siebert CH (2003) Transient osteoporosis of the navicular bone in a runner. Arch Orthop Trauma Surg 123:505–508PubMedCrossRef

52.

Minsker DH, Manson JM, Peter CP (1993) Effects of the bisphosphonate, alendronate, on parturition in the rat. Toxicol Appl Pharmacol 121:217–223PubMedCrossRef

53.

Murguia MJ, Vailas A, Mandelbaum B, Norton J, Hodgdon J, Goforth H, Riedy M (1988) Elevated plasma hydroxyproline. A possible risk factor associated with connective tissue injuries during overuse. Am J Sports Med 16:660–664PubMedCrossRef

54.

Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294–1301PubMedCrossRef

55.

Ott SM (2001) Fractures after long-term alendronate therapy. J Clin Endocrinol Metab 86:1835–1836PubMedCrossRef

56.

Parker L (1999) I.v. devices and related infections: causes and complications. Br J Nurs 8:1491–1498PubMed

57.

Patlas N, Golomb G, Yaffe P, Pinto T, Breuer E, Ornoy A (1999) Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology 60:68–73PubMedCrossRef

58.

Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P (2007) A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 29:1548–1558PubMedCrossRef

59.

Pepper M, Akuthota V, McCarty EC (2006) The pathophysiology of stress fractures. Clin Sports Med 25:1–16PubMedCrossRef

60.

Ramachandran M, Ward K, Brown RR, Munns CF, Cowell CT, Little DG (2007) Intravenous BP therapy for traumatic osteonecrosis of the femoral head in adolescents. J Bone Joint Surg Am 89:1727–1734PubMedCrossRef

61.

Ringe JD, Dorst A, Faber H (2005) Effective and rapid treatment of painful localized transient osteoporosis (bone marrow edema) with intravenous ibandronate. Osteoporos Int 16:2063–2068PubMedCrossRef

62.

Ringe JD, Body JJ (2007) A review of bone pain relief with ibandronate and other bisphosphonates in disorders of increased bone turnover. Clin Exp Rheumatol 25:766–774PubMed

63.

Russell RG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733–759PubMedCrossRef

64.

Saito M, Mori S, Mashiba T, Komatsubara S, Marumo K (2008) Collagen maturity, glycation induced-pentosidine, and mineralization are increased following 3-year treatment with incadronate in dogs. Osteoporos Int 19:1343–1354PubMedCrossRef

65.

Santini D, Vincenzi B, Galluzzo S, Battistoni F, Rocci L, Venditti O, Schiavon G, Angeletti S, Uzzalli F, Caraglia M, Dicuonzo G, Tonini G (2007) Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 13:4482–4486PubMedCrossRef

66.

Shaffer SW, Uhl TL (2006) Preventing and treating lower extremity stress reactions and fractures in adults. J Athl Train 41:466–469PubMed

67.

Shane E, Goldring S, Christakos S, Drezner M, Eisman J, Silverman S, Pendrys D (2006) Osteonecrosis of the jaw: more research needed. J Bone Miner Res 21:1503–1505PubMedCrossRef

68.

Siegmund T, Allen MR, Burr DB (2008) Failure of mineralized collagen fibrils: modeling the role of collagen cross-linking. J Biomech 41:1427–1435PubMedCrossRef

69.

Siris ES (1993) Bisphosphonates and iritis. Lancet 341:436–437PubMedCrossRef

70.

Smith EJ, Little DG, Briody JN, McEvoy A, Smith NC, Eisman JA, Gardiner EM (2005) Transient disturbance in physeal morphology is associated with long-term effects of nitrogen-containing bisphosphonates in growing rabbits. J Bone Miner Res 20:1731–1741PubMedCrossRef

71.

Stewart GW, Brunet ME, Manning MR, Davis FA (2005) Treatment of stress fractures in athletes with intravenous pamidronate. Clin J Sport Med 15:92–94PubMedCrossRef

72.

Taki M, Iwata O, Shiono M, Kimura M, Takagishi K (2007) Extracorporeal shock wave therapy for resistant stress fracture in athletes: a report of 5 cases. Am J Sports Med 35:1188–1192PubMedCrossRef

73.

Thiébaud D, Sauty A, Burckhardt P, Leuenberger P, Sitzler L, Green JR, Kandra A, Zieschang J, Ibarra de Palacios P (1997) An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int 61:386–392PubMedCrossRef

74.

Thompson K, Rogers MJ (2004) Statins prevent bisphosphonate-induced gamma, delta-T-cell proliferation and activation in vitro. J Bone Miner Res 19:278–288PubMedCrossRef

75.

Tonino RP, Meunier PJ, Emkey R, Rodriguez-Portales JA, Menkes CJ, Wasnich RD, Bone HG, Santora AC, Wu M, Desai R, Ross PD (2000) Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 85:3109–3115PubMedCrossRef

76.

Tonino RP (2001) Safety of long-term alendronate. J Clin Endocrinol Metab 86:1835–1836CrossRef

77.

van Meerten EL, Kroon HM, Papapoulos SE (1992) Epi- and metaphyseal changes in children caused by administration of bisphophonates. Radiology 184:249–254

78.

Ward K, Cowell CT, Little DG (2005) Quantification of metaphyseal modeling in children treated with bisphosphonates. Bone 36:999–1002PubMedCrossRef

79.

Välimäki VV, Alfthan H, Lehmuskallio E, Löyttyniemi E, Sahi T, Suominen H, Välimäki MJ (2005) Risk factors for clinical stress fractures in male military recruits: a prospective cohort study. Bone 37:267–273PubMedCrossRef

80.

Weinstein RS, Chen JR, Powers CC, Stewart SA, Landes RD, Bellido T, Jilka RL, Parfitt AM, Manolagas SC (2002) Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest 109:1041–1048PubMed

81.

Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S (2003) Bisphosphonate-induced osteopetrosis. N Engl J Med 349:457–463PubMedCrossRef

82.

Woo SB, Hellstein JW, Kalmar JR (2006) Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753–761PubMed

83.

Wood J, Bonjean K, Ruetz S, Bellahcène A, Devy L, Foidart JM, Castronovo V, Green JR (2002) Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302:1055–1061PubMedCrossRef

84.

Wysowski DK, Chang J (2005) Alendronate and risedronate: reports of severe bone, joint, and muscle pain. Arch Intern Med 165:346–347PubMedCrossRef

Title: Use of bisphosphonates for the treatment of stress fractures in athletes
Authors: Yosuke Shima
Lars Engebretsen
Junji Iwasa
Katsuhiko Kitaoka
Katsuro Tomita
Publication date: 01-05-2009
Publisher: Springer-Verlag
Published in: Knee Surgery, Sports Traumatology, Arthroscopy / Issue 5/2009
Print ISSN: 0942-2056
Electronic ISSN: 1433-7347
DOI: https://doi.org/10.1007/s00167-008-0673-0

At a glance: The STEP trials

Springer Medicine

Use of bisphosphonates for the treatment of stress fractures in athletes

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2009

A mini-invasive adductor magnus tendon transfer technique for medial patellofemoral ligament reconstruction: a technical note

Reply to the comments on our article “The fate of patellar tendon and infrapatellar fat pad after arthroscopy via central portal”

Do not use bisphosphonates without scientific evidence, neither in treatment nor prophylactic, in the treatment of stress fractures

An unusual periarticular fracture following ipsilateral anterior cruciate ligament reconstruction

Predicting range of movement after knee replacement: the importance of posterior condylar offset and tibial slope

Outcome of double-bundle ACL reconstruction using hamstring tendons